| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
BOSTON—With an ambitious goal and perhaps even moreambitious timetable, the National Brain Tumor Society announced March 26 the formationof the Defeat GBM Research Collaborative, a strategic research initiative witha goal to double the five-year survival rate of patients with glioblastomamultiforme (GBM)—the most common and deadliest form of brain cancer—in justfive years.
 
 
To achieve this goal, those running the Defeat GBMResearch Collaborative plan to connect leading brain tumor researchers from topcancer institutions across the globe, in a "tightly focused and goal-driven effort,"the National Brain Tumor Society says. "Through research collaboration,synergistic projects will be combined and driven by investigator teams withproven track records of results to create significant improvement in patient survival."
 
 
The primary goal will be to share data among allprojects and investigator teams within Defeat GBM to better inform the overalleffort and to advance potential therapies down the drug discovery pipeline.
 
 
"Defeat GBM draws upon successful science andproven funding models from other disease populations that have yet to beutilized in brain tumor research," said N. Paul TonThat, executive director ofthe National Brain Tumor Society. "The brain tumor community can no longerspend years and millions of dollars to achieve only incremental progress inthis deadly disease."
 
 
Participating researchers and investigator teamsfor key projects within Defeat GBM will initially stem from such institutions asthe University of Texas MD Anderson Cancer Center and the Ludwig Institute forCancer Research. The Initiative will also actively collaborate with theNational Foundation for Cancer Research (NFCR) on a parallel bioinformatics andGBM genomics project, which capitalizes on NFCR's longstanding relationshipwith the Tissue Bank Consortium in Tianjin, China.
 
 
The National Brain Tumor Society touts various "additionaland unique aspects" of the program, which include simultaneous research effortsin basic discovery science, translational science, preclinical drug developmentand clinical trial design, all of which is "intended to identify the rightbiological targets and attack them with the right therapies in the right patients."
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue